Shree Ganesh Remedies Q4 FY26 Results: PAT of Rs 6.26 crore Pharmaceuticals and APIs

Shree Ganesh Remedies results were announced on May 14, 2026, at the company’s board meeting. the company PAT was Rs 6.26 crore. The pharmaceutical company manufactures APIs and pharmaceutical formulations for domestic and export markets. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Shree Ganesh Remedies Q4 FY26 Key Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 6.26 crore	Q4 FY25 / Reference
Ticker	SHREEGAN	Sector: Pharmaceuticals and APIs

Screen the best stocks on the Univest Screener.

Shree Ganesh Remedies Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. the company PAT was Rs 6.26 crore. The pharmaceutical company manufactures APIs and pharmaceutical formulations for domestic and export markets. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Shree Ganesh Remedies FY27 Outlook

Post Shree, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharmaceuticals and APIs space. The Shree results demonstrate the company’s execution capabilities. Track Shree updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Shree Ganesh Remedies Q4 FY26 Results

What is it PAT?

Ans. Shree profit after tax was Rs 6.26 crore.

When did Shree Ganesh Remedies announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Shree Ganesh Remedies?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharmaceuticals and APIs sector. Track live updates on the Univest Screener.

Where can I track the company live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.